Ribonucleotide reductase as a chemotherapeutic target

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Therapeutics

Background:

• Ribonucleotide reductase (RR) is crucial for DNA replication and a viable target for cancer chemotherapy.
• RR's unique protein subunits and critical role in DNA synthesis present specific therapeutic vulnerabilities.

Purpose of the Study:

• To investigate the synergistic effects of combining different ribonucleotide reductase inhibitors for cancer treatment.
• To explore the impact of targeting RR subunits and substrate reduction sensitivities on cancer cell proliferation.

Main Methods:

• Utilized a combination of RR inhibitors targeting non-heme iron and effector-binding subunits.
• Assessed the impact of these inhibitors on intracellular dNTP pools and DNA polymerase activity.
• Evaluated the relationship between DNA synthesis rates and cancer cell viability.

Main Results:

• Combined RR inhibitors demonstrated synergistic inhibition of cancer cell growth and induced cytotoxicity.
• Inhibition of RR led to a sigmoidal reduction in DNA polymerase activity due to dNTP pool depletion.
• Significant decreases in dNTPs resulted in substantial reductions in DNA synthesis and cell replication.

Conclusions:

• Combined inhibition of ribonucleotide reductase is a promising chemotherapeutic strategy for cancer.
• The sigmoidal relationship between dNTP levels and DNA synthesis amplifies the cytotoxic effects of RR inhibition.
• Cancer cell viability is intrinsically linked to maintaining a minimal DNA synthesis rate, making RR inhibition a potent cell death inducer.